NLS Pharmaceutics Announces Patent Issuance in the United States for its Mazindol Extended-Release Formulation

Key patent now granted in major markets including the U.S., Europe, Canada & South KoreaPatent claims cover use of the Company's lead product candidate, Quilience® (mazindol ER) in both attention deficit hyperactivity disorder (ADHD) & …